Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech’s history in terms of operating cash flowsContinued expansion of commercial partnerships for pipeline assetsAlvotech listed on Nasdaq Stockholm MarketConference call and live webcast on Thursday August 14, 2025, 8:00 am ET (12:00pm GMT) REYKJAVIK, Iceland, August 13, 2025 - Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar med ...

Financial Performance & Outlook - Alvotech's revised outlook for 2025 projects revenues between $600 million and $700 million, including product revenue of $340 million to $410 million and milestone revenues of $260 million to $290 million[12] - The company anticipates an adjusted EBITDA of $200 million to $280 million in 2025[12] - Alvotech expects a product margin of 38-41% and a gross margin of 65-66%[12] - Q1 2025 product revenue reached $110 million, a 784% increase compared to $12 million in Q1 2024[34] - Total revenue for Q1 2025 was $133 million, a 260% increase from $37 million in Q1 2024[34] Product Pipeline & Commercialization - Alvotech has a robust pipeline of biosimilar candidates, including AVT02 (adalimumab), AVT04 (ustekinumab), and others in various stages of development and commercialization[23] - The company expects >50% of the U S Humira® market to convert to biosimilars before the end of 2025[25] - SELARSDI® (Stelara® biosimilar) has been approved in the U S as an interchangeable biosimilar for all presentations[25] Cash Flow & Capital Structure - Alvotech had cash and cash equivalents of $39 million as of March 31, 2025, with total borrowings of $1,097 million[40] - The company anticipates being free cash flow positive in 2025 based on current operating plans[40] - As of March 31, 2025, there were 301.9 million common shares outstanding[40]

Full Year 2024 Earnings and Business Update March 27, 2025 Disclaimer This presentation ("Presentation") does not contain or constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security of Alvotech (the "Company") to any person in the United States or in any jurisdiction to whom or in which such offer or solicitation is unlawful. Any trademarks, servicemarks, trade names and copyrights of the Company and other companies contained in this Presentation are the p ...